Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 421 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin Placebo Clear all
Completed Phase 3 Interventional Results available

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

NCT01825798
View directory record Official record
Conditions
Overweight, Autism Spectrum Disorder
Interventions
Metformin, Placebo
Drug
Lead sponsor
Holland Bloorview Kids Rehabilitation Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

NCT03332771
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
115
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

NCT02597101
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Metformin, saxagliptin, AZD9668, placebo
Drug
Lead sponsor
Nick Giannoukakis, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00039013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin Effects on Epicardial Fat

NCT02235298
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin During Nicotine Withdrawal

NCT03593538
View directory record Official record
Conditions
Smoking, HIV-1-infection
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

NCT00110851
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, metformin, PN2034
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 72 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

NCT01103622
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Digoxin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Oct 2, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

NCT00313313
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Glyburide, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
54
States / cities
Jonesboro, Arkansas • Searcy, Arkansas • Alhambra, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

NCT01298518
View directory record Official record
Conditions
Type 2 Diabetes Patients
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Chula Vista, California • DeLand, Florida • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

NCT00757588
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, 5 mg + insulin, Placebo + insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glimepiride
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Oct 2, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 2, 2026, 7:41 PM EDT